Safety and Efficacy of Acarbose+Saxagliptin Compared With Metformin+Saxagliptin in Patients With Type 2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

Also called NCT02605772

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Fifth Affiliated Hospital, Sun Yat-Sen University (from the registry)
Registry
  • NCT NCT02605772
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02605772. Randomized; no masking; primary purpose treatment. Start 2015-12 (registry gives no type); primary completion 2016-11 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of Acarbose+Saxagliptin Compared With Metformin+Saxagliptin in Patients With Type 2 Diabetes
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Acarbose
Intervention (Drug)
Metformin
Intervention (Drug)
Saxagliptin
Lead sponsor
Fifth Affiliated Hospital, Sun Yat-Sen University (class: other)

Record details

Record id
cardio:ct-nct02605772
Content hash
a86dc0b2868c36e962861216d4f27a4441b0a919e40f1dda8835c74f37bed6bb